Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.

To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
IPWatchdog Sixth Annual Live Conference
Speaking Engagement
Intellectual Property
The DOJ's Whistleblower Program and Leniency
Axinn Viewpoints
Antitrust
Squires Again Broadens Discretion for Post-Grant Proceedings
Axinn Viewpoints
Intellectual Property
ABA White Collar Crime Institute 2026
Speaking Engagement
Back to the Well: FDA’s Draft Guidance on New Clinical Investigation Exclusivity
Axinn Viewpoints
Intellectual Property
Mother, May I? The Use of Prior Approval Requirements in Merger Settlements
Podcast
Antitrust
The Curtain Rises Again on FTC Act Section 5
Axinn Viewpoints
Jeny Maier Named Finalist for Managing Partner of the Year in 2026 Women, Influence & Power in Law Awards
Awards & Recognitions

